Development of a first in class inhibitor of BET bromodomains and dopamine receptor 2

被引：0
|
作者：
Yoshioka, Makoto
Chauhan, Jay
Fletcher, Steven
Strovel, Jeffrey W.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-5062
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5062
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The Making of I-BET762, a BET Bromodomain Inhibitor Now in Clinical Development
    Zhao, Yujun
    Yang, Chao-Yie
    Wang, Shaomeng
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (19) : 7498 - 7500
  • [22] Development of the BET bromodomain inhibitor OTX015
    Noel, J. Kay
    Iwata, Kazunori
    Ooike, Shinsuke
    Sugahara, Kunio
    Nakamura, Hideo
    Daibata, Masanori
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [23] Development and preclinical assessment of a first-in-class small molecule inhibitor of FLIP
    Majkut, Joanna
    Higgins, Catherine
    Fox, Jennifer
    Fiedler, Greti E.
    Harrison, Timothy
    Longley, Daniel B.
    CANCER RESEARCH, 2017, 77
  • [24] Identification of potent and selective small molecule inhibitors of the BET family bromodomains demonstrate the tractability of a new class of epigenetic targets for drug discovery
    Chung, Chun-wa
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [25] Reversal of dopamine D2 receptor responses by an anandamide transport inhibitor
    Beltramo, M
    de Fonseca, FR
    Navarro, M
    Calignano, A
    Gorriti, MA
    Grammatikopoulos, G
    Sadile, AG
    Giuffrida, A
    Piomelli, D
    JOURNAL OF NEUROSCIENCE, 2000, 20 (09): : 3401 - 3407
  • [26] Development of a Bivalent Dopamine D2 Receptor Agonist
    Kuehhorn, Julia
    Goetz, Angela
    Huebner, Harald
    Thompson, Dawn
    Whistler, Jennifer
    Gmeiner, Peter
    JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (22) : 7911 - 7919
  • [27] A D2 class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission
    Kotecha, SA
    Oak, JN
    Jackson, MF
    Perez, Y
    Orser, BA
    Van Tol, HHM
    MacDonald, JF
    NEURON, 2002, 35 (06) : 1111 - 1122
  • [28] Discovery of a first-in-class ERK 1,2 inhibitor
    Samatar, Ahmed A.
    MOLECULAR CANCER RESEARCH, 2014, 12
  • [29] Development of Bevirimat (PA-457): first-in-class HIV maturation inhibitor
    Allaway, Graham P.
    RETROVIROLOGY, 2006, 3 (Suppl 1)
  • [30] DEVELOPMENT OF THE FIRST-IN-CLASS INHIBITOR OF CHD4-SENSITIZING RESISTANT GLIOMAS
    Nurmemmedov, Elmar
    Kesari, Santosh
    NEURO-ONCOLOGY, 2020, 22 : 63 - 63
12345